Technology ID
TAB-3570
Novel Dual 5-lipoxgenase and East CYP51 Inhibitors for the Treatment of Dandruff
E-Numbers
E-217-2013-0
Lead Inventor
Holman, Theodore (University of California, Santa Cruz)
Co-Inventors
Maloney, David (NCATS)
Jadhav, Ajit (NCATS)
Rai Bantukallu, Ganesha (NCATS)
Simeonov, Anton (NCATS)
Kelly, Steven (Swansea University)
Applications
Therapeutics
Research Materials
Therapeutic Areas
Ophthalmology
Oncology
Infectious Disease
Endocrinology
Dental
Cardiology
Lead IC
NCATS
ICs
NCATS
This technology includes a newly designed chemical molecule that is both an antifungal agent, by inhibiting CYP51,
and an anti-inflammatory agent, by inhibiting 5-lipoxygenase, for the treatment of dandruff. Both of these properties would be useful for antifungal treatments, and both of these attributes are required to combat dandruff. However,
typical therapies involve treating the infection and inflammation separately.
Commercial Applications
Utilized for the treatment of dandruff.
Competitive Advantages
Single agent therapy for dandruff with a dual mechanism.
Licensing Contact: